> Research Notice: Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy in adults. This article summarizes clinical and research literature for educational purposes. Off-label research use should be conducted only by qualified investigators following applicable regulations.
What Is Tesamorelin?
Tesamorelin (developmental code: TH9507; brand name: Egrifta) is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid GHRH(1-44) sequence conjugated at the N-terminus with trans-3-hexenoic acid. This chemical modification stabilizes the peptide against rapid N-terminal cleavage by dipeptidyl peptidase IV (DPP-IV), extending biological half-life from minutes (for native GHRH) to approximately 20–30 minutes.
Tesamorelin holds FDA approval as Egrifta SV (2020 reformulation) for the reduction of excess abdominal fat (visceral adiposity) in adults with HIV on antiretroviral therapy who have developed lipodystrophy — making it one of the few research peptides with full regulatory approval and an established clinical evidence base. The compound is manufactured by Theratechnologies Inc.
Structure
- •Amino acid sequence: Trans-3-hexenoic acid — Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
- •Molecular weight: Approximately 5,135 Da
- •Half-life: ~20–30 minutes (subcutaneous)
- •Route of administration: Subcutaneous injection
Mechanism of Action
Tesamorelin acts as a full agonist at the pituitary growth hormone-releasing hormone receptor (GHRH-R), triggering a signaling cascade that stimulates the synthesis and pulsatile secretion of endogenous growth hormone (GH). Unlike exogenous recombinant human growth hormone (rhGH), tesamorelin works by amplifying the body's own GH secretory axis — preserving the physiological pulsatility of GH release and the negative feedback mechanisms that prevent supraphysiological elevations.
GH-IGF-1 Axis Stimulation
Upon binding to pituitary GHRH receptors, tesamorelin activates adenylate cyclase via Gs proteins, increasing intracellular cyclic AMP (cAMP) and triggering calcium-dependent GH exocytosis. The subsequent GH pulse drives hepatic insulin-like growth factor-1 (IGF-1) synthesis and secretion. Elevated IGF-1 mediates many of tesamorelin's downstream effects — including lipolysis in visceral adipose tissue, protein anabolic effects in muscle, and hepatic metabolic modulation.
Visceral Adipose Tissue Reduction
Tesamorelin's primary clinical application targets visceral adipose tissue (VAT) — the metabolically active, inflammation-generating fat depot surrounding abdominal organs. Elevated VAT is a hallmark of HIV-associated lipodystrophy, driven by antiretroviral drug toxicity and dysregulated adipogenesis. Through GH/IGF-1 axis stimulation, tesamorelin increases lipolysis within VAT depots, reduces adipocyte size, and lowers circulating triglycerides. CT-scan-measured VAT reductions of 15–20% have been documented in clinical trials.
DPP-IV Resistance
The trans-3-hexenoic acid N-terminal modification that distinguishes tesamorelin from native GHRH provides resistance to DPP-IV cleavage — the primary degradation mechanism for endogenous GHRH. This chemical stabilization dramatically extends biological activity compared to GHRH(1-44) or short GHRH analogs like sermorelin, while maintaining full receptor binding affinity and GH secretory potency.
Key Research Studies
Pivotal Phase 3 Clinical Trial (NEJM, 2007)
Falutz J, Allas S, Blot K, et al., "Metabolic effects of a growth hormone-releasing factor in patients with HIV," New England Journal of Medicine, 2007 (PMID: 18057338). This landmark randomized, double-blind, placebo-controlled trial enrolled 412 HIV-positive adults with lipodystrophy across multiple sites in North America and Europe. Participants received tesamorelin 2 mg subcutaneously once daily or placebo for 26 weeks. The tesamorelin group achieved a statistically significant 15.2% reduction in visceral adipose tissue (measured by CT scan) compared to a 5.0% increase in the placebo group. Improvements in triglycerides, waist circumference, and patient-reported body image were also documented. This trial formed the primary basis for FDA approval.
Systematic Review and Meta-Analysis (2025)
Ditta AM, Naeem RM, Sami MM, et al., "Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis," Journal of the International Association of Providers of AIDS Care, 2025 (PMID: 42538058). This comprehensive synthesis of available clinical evidence confirmed that tesamorelin consistently reduces VAT, improves lipid profiles, and is generally well-tolerated in the HIV lipodystrophy population. The meta-analysis further characterizes the magnitude of effect across diverse study populations and durations.
Body Composition and Hepatic Fat Analysis (2025)
Badran AS, Helal A, Shata KS, Ayesh H, "Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis," Obesity Research & Clinical Practice, 2025 (PMID: 41545261). This meta-analysis included analysis of hepatic fat reduction alongside VAT changes, finding that tesamorelin additionally reduces liver fat content in HIV-associated steatohepatitis — an emerging clinical application with significant hepatological implications.
Lipodystrophy Clinical Framework (2022)
Fourman LT, Grinspoon SK, "Approach to the Patient With Lipodystrophy," Journal of Clinical Endocrinology and Metabolism, 2022 (PMID: 35137140). This clinical review from researchers at Massachusetts General Hospital and Harvard Medical School details the diagnostic and therapeutic framework for lipodystrophy, placing tesamorelin within the broader treatment landscape and discussing its role in HIV-related and other forms of lipodystrophy.
Research Applications
HIV-Associated Lipodystrophy
The primary and best-characterized research application involves the pathophysiology and treatment of antiretroviral therapy-induced lipodystrophy — a syndrome characterized by peripheral fat loss (lipoatrophy), central fat accumulation (visceral adiposity), dyslipidemia, and insulin resistance. Tesamorelin's FDA approval makes it a clinical standard-of-care compound for this indication, and ongoing research explores optimal duration of treatment, predictors of response, and long-term metabolic outcomes.
Hepatic Steatosis in HIV
Emerging research investigates tesamorelin's hepatic effects, given the high prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in HIV-positive individuals. Studies suggest that GH/IGF-1 axis normalization reduces hepatic fat accumulation — an effect potentially relevant beyond the HIV context.
Cognitive Function Research
A distinct research thread examines whether GH/IGF-1 axis stimulation via tesamorelin improves cognitive function in HIV-positive individuals, who experience disproportionately high rates of HIV-associated neurocognitive disorder (HAND). Pilot studies have demonstrated improvements in executive function and verbal memory — hypothesized to occur through IGF-1-mediated neuroprotective effects.
Cardiovascular Risk Reduction
Given that visceral adiposity is a major independent cardiovascular risk factor, researchers have investigated whether VAT reduction via tesamorelin translates into cardiovascular benefit — including reductions in carotid intima-media thickness, inflammatory biomarkers, and triglyceride-rich lipoproteins.
Body Composition Research
Tesamorelin is used as a research tool in body composition studies — given its selective VAT-reducing effects (unlike direct lipolytic agents that affect subcutaneous fat non-selectively). The selectivity for visceral fat depots makes it a valuable tool for dissecting the independent metabolic contributions of VAT versus subcutaneous adipose tissue.
Reconstitution and Storage
The following is provided for qualified researchers and clinicians. Tesamorelin (Egrifta) is a prescription medication; off-label research should follow institutional guidelines.
Reconstitution (Egrifta SV formulation): Each vial contains tesamorelin 2 mg as a lyophilized powder. Reconstitute with 2.1 mL of provided sterile water for injection; inject solvent gently along the wall of the vial to avoid foaming. Swirl gently — do not shake. The reconstituted solution should appear clear and colorless.
Stability: Lyophilized powder is stable at room temperature (up to 25°C/77°F) for up to 3 months, or refrigerated at 2–8°C for up to 24 months. Once reconstituted, use immediately or refrigerate for up to 3 hours only — discard any unused reconstituted solution. Do not freeze the reconstituted solution.
Research-grade tesamorelin from peptide suppliers follows similar reconstitution principles, though researchers should verify stability data from their specific supplier.
Sourcing Guide
Tesamorelin is available through two channels for researchers:
Clinical prescription: As Egrifta SV, through licensed pharmacies with a valid prescription from a physician — primarily for HIV lipodystrophy management.
Research-grade sources: For non-clinical research, pharmaceutical-grade or high-purity synthetic tesamorelin is available from established research peptide suppliers with documented quality control. Key quality metrics to verify:
- •HPLC purity ≥98%
- •Mass spectrometry confirmation of the 44-amino acid sequence with N-terminal modification
- •Sterility testing documentation for in vivo research preparations
- •Certificate of Analysis (CoA) with batch-level results
Compare current research-grade tesamorelin suppliers, pricing, and purity documentation on the Peptides.SO Tesamorelin comparison page.
Related peptides for researchers studying the GHRH axis include sermorelin, CJC-1295, and CJC-1295 DAC — which differ in half-life, receptor selectivity, and mechanism of GH secretion stimulation.
Frequently Asked Questions
Why is tesamorelin considered different from sermorelin or CJC-1295?
Tesamorelin contains the full 44-amino acid GHRH sequence (sermorelin contains only 29 amino acids), providing a more complete receptor activation profile. The N-terminal trans-3-hexenoic acid modification uniquely extends half-life through DPP-IV resistance, without requiring albumin binding (as in CJC-1295 DAC). This combination of full-length sequence and enzymatic stability gives tesamorelin a distinct pharmacokinetic and pharmacodynamic profile — and the only FDA approval among GHRH analogs.
Is tesamorelin studied only in HIV patients?
No. While the primary approved indication and clinical trial database is HIV-associated lipodystrophy, researchers are actively investigating tesamorelin in other contexts — including metabolic dysfunction-associated steatotic liver disease (MASLD), age-related GH decline, obesity-related VAT accumulation, and cognitive impairment. The FDA approval provides a well-characterized safety and efficacy foundation for these investigational directions.
What side effects have been documented in clinical trials?
The most common adverse effects in clinical trials include injection site reactions (erythema, pruritus), fluid retention/edema, arthralgia, myalgia, and peripheral neuropathy. These are generally mild to moderate and related to GH pathway activation. IGF-1 elevation should be monitored; tesamorelin is contraindicated in active malignancy due to potential IGF-1-driven growth effects.
Does tesamorelin increase risk of diabetes?
GH excess can impair insulin sensitivity; however, clinical trials with tesamorelin have not demonstrated a clinically significant increase in diabetes incidence at standard doses. Some patients experience transient glucose elevations, requiring monitoring in those with pre-existing glucose tolerance issues.
How long do VAT-reduction effects persist after stopping tesamorelin?
Studies indicate that VAT gains return within 6–12 months of discontinuing tesamorelin, suggesting ongoing therapy is needed to maintain the visceral fat reduction benefit. This observation has driven research into intermittent dosing strategies.
---
Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy. Off-label research or clinical use should be undertaken only by qualified medical professionals following applicable regulatory guidelines. This article is for educational purposes only.